BMS Receives the EC Approval for Opdivo (nivolumab) + CT as Neoadjuvant Treatment of Resectable Stage IB to IIIA Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients
- The approval is based on P-III study (CheckMate –816) data that evaluated Opdivo (360mg) + CT (Q3W for 3 cycles) vs CT alone. in which Opdivo + CT showed improvement in 1EP (mEFS & pCR) and 2EP (OS)
- At 21mos. follow-up in all-randomized patients (n=358), mEFS was (31.6mos. vs (20.8mos.) and pCR was (24% vs 2.2%). OS showed a reduction in the risk of death by 43% vs CT alone. The safety profile was consistent with previously reported studies in NSCLC
- Opdivo is a PD-1 ICI, tackle the body’s immune system to help restore anti-tumor immune response across multiple cancers
Ref: BMS | Image: BMS
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.